AbbVie Inc.
10-Q · 2020-05-08T00:00:00Z · 0001551152-20-00001561 tables
Cover (1)
Statements (7)
- R2.htmCondensed Consolidated Statements of Earnings (Unaudited)
1001000 - Statement - Condensed Consolidated Statements of Earnings (Unaudited)
- R3.htmCondensed Consolidated Statements of Comprehensive Income (Unaudited)
1002000 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)
- R4.htmCondensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited)
1002501 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (Unaudited)
- R5.htmCondensed Consolidated Balance Sheets
1003000 - Statement - Condensed Consolidated Balance Sheets
- R6.htmCondensed Consolidated Balance Sheets (Parenthetical)
1003501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)
- R7.htmCondensed Consolidated Statements of Equity (Unaudited)
1004000 - Statement - Condensed Consolidated Statements of Equity (Unaudited)
- R8.htmCondensed Consolidated Statements of Cash Flows (Unaudited)
1005000 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)
Notes (13)
- R9.htmBasis of Presentation
2101100 - Disclosure - Basis of Presentation
- R10.htmSupplemental Financial Information
2103100 - Disclosure - Supplemental Financial Information
- R11.htmEarnings Per Share
2104100 - Disclosure - Earnings Per Share
- R12.htmLicensing, Acquisitions, and Other Arrangements
2105100 - Disclosure - Licensing, Acquisitions, and Other Arrangements
- R13.htmCollaboration with Janssen Biotech, Inc.
2106100 - Disclosure - Collaboration with Janssen Biotech, Inc.
- R14.htmGoodwill and Intangible Assets
2107100 - Disclosure - Goodwill and Intangible Assets
- R15.htmRestructuring Plans
2108100 - Disclosure - Restructuring Plans
- R16.htmFinancial Instruments and Fair Value Measures
2110100 - Disclosure - Financial Instruments and Fair Value Measures
- R17.htmPost-Employment Benefits
2111100 - Disclosure - Post-Employment Benefits
- R18.htmEquity
2112100 - Disclosure - Equity
- R19.htmIncome Taxes
2113100 - Disclosure - Income Taxes
- R20.htmLegal Proceedings and Contingencies
2114100 - Disclosure - Legal Proceedings and Contingencies
- R21.htmSegment Information
2115100 - Disclosure - Segment Information
Policies (1)
Tables (9)
- R23.htmSupplemental Financial Information (Tables)
2303301 - Disclosure - Supplemental Financial Information (Tables)
- R24.htmEarnings Per Share (Tables)
2304301 - Disclosure - Earnings Per Share (Tables)
- R25.htmCollaboration with Janssen Biotech, Inc. (Tables)
2306301 - Disclosure - Collaboration with Janssen Biotech, Inc. (Tables)
- R26.htmGoodwill and Intangible Assets (Tables)
2307301 - Disclosure - Goodwill and Intangible Assets (Tables)
- R27.htmRestructuring Plans (Tables)
2308301 - Disclosure - Restructuring Plans (Tables)
- R28.htmFinancial Instruments and Fair Value Measures (Tables)
2310301 - Disclosure - Financial Instruments and Fair Value Measures (Tables)
- R29.htmPost-Employment Benefits (Tables)
2311301 - Disclosure - Post-Employment Benefits (Tables)
- R30.htmEquity (Tables)
2312301 - Disclosure - Equity (Tables)
- R31.htmSegment Information (Tables)
2315301 - Disclosure - Segment Information (Tables)
Details (30)
- R32.htmBasis of Presentation (Details)
2401402 - Disclosure - Basis of Presentation (Details)
- R33.htmSupplemental Financial Information (Details)
2403402 - Disclosure - Supplemental Financial Information (Details)
- R34.htmEarnings Per Share (Details)
2404402 - Disclosure - Earnings Per Share (Details)
- R35.htmLicensing, Acquisitions, and Other Arrangements - Proposed Acquisition of Allergan plc (Details)
2405401 - Disclosure - Licensing, Acquisitions, and Other Arrangements - Proposed Acquisition of Allergan plc (Details)
- R36.htmLicensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details)
2405402 - Disclosure - Licensing, Acquisitions, and Other Arrangements - Other Licensing & Acquisitions Activity (Details)
- R37.htmCollaboration with Janssen Biotech, Inc. (Details)
2406402 - Disclosure - Collaboration with Janssen Biotech, Inc. (Details)
- R38.htmGoodwill and Intangible Assets - Goodwill (Details)
2407402 - Disclosure - Goodwill and Intangible Assets - Goodwill (Details)
- R39.htmGoodwill and Intangible Assets - Intangible Assets, Net (Details)
2407403 - Disclosure - Goodwill and Intangible Assets - Intangible Assets, Net (Details)
- R40.htmRestructuring Plans (Details)
2408402 - Disclosure - Restructuring Plans (Details)
- R41.htmFinancial Instruments and Fair Value Measures - Financial Instruments (Details)
2410402 - Disclosure - Financial Instruments and Fair Value Measures - Financial Instruments (Details)
- R42.htmFinancial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details)
2410403 - Disclosure - Financial Instruments and Fair Value Measures - Amount Of Gain/(Loss) Recognized For Derivative Instruments (Details)
- R43.htmFinancial Instruments and Fair Value Measures - Fair Value Measures (Details)
2410404 - Disclosure - Financial Instruments and Fair Value Measures - Fair Value Measures (Details)
- R44.htmFinancial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)
2410405 - Disclosure - Financial Instruments and Fair Value Measures - Significant Level 3 Unobservable Inputs (Details)
- R45.htmFinancial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details)
2410406 - Disclosure - Financial Instruments and Fair Value Measures - Transfers of Assets or Liabilities Into or Out of Level 3 of the Fair Value Hierarchy (Details)
- R46.htmFinancial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details)
2410407 - Disclosure - Financial Instruments and Fair Value Measures - Bases Used To Measure The Approximate Fair Values Of Financial Instruments (Details)
- R47.htmFinancial Instruments and Fair Value Measures - Concentrations of Risk (Details)
2410408 - Disclosure - Financial Instruments and Fair Value Measures - Concentrations of Risk (Details)
- R48.htmFinancial Instruments and Fair Value Measures - Debt and Credit Facilities (Details)
2410409 - Disclosure - Financial Instruments and Fair Value Measures - Debt and Credit Facilities (Details)
- R49.htmFinancial Instruments and Fair Value Measures - Short-Term Borrowings (Details)
2410410 - Disclosure - Financial Instruments and Fair Value Measures - Short-Term Borrowings (Details)
- R50.htmPost-Employment Benefits (Details)
2411402 - Disclosure - Post-Employment Benefits (Details)
- R51.htmEquity - Stock-Based Compensation (Details)
2412402 - Disclosure - Equity - Stock-Based Compensation (Details)
- R52.htmEquity - Stock Options (Details)
2412403 - Disclosure - Equity - Stock Options (Details)
- R53.htmEquity - RSUs and Performance Shares (Details)
2412404 - Disclosure - Equity - RSUs and Performance Shares (Details)
- R54.htmEquity - Cash Dividends (Details)
2412405 - Disclosure - Equity - Cash Dividends (Details)
- R55.htmEquity - Stock Repurchase Program (Details)
2412406 - Disclosure - Equity - Stock Repurchase Program (Details)
- R56.htmEquity - Accumulated Other Comprehensive Loss (Details)
2412407 - Disclosure - Equity - Accumulated Other Comprehensive Loss (Details)
- R57.htmEquity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details)
2412408 - Disclosure - Equity - Amounts Reclassified Out Of Accumulated Other Comprehensive Loss (Details)
- R58.htmIncome Taxes (Details)
2413401 - Disclosure - Income Taxes (Details)
- R59.htmLegal Proceedings and Contingencies (Details)
2414401 - Disclosure - Legal Proceedings and Contingencies (Details)
- R60.htmSegment Information - Additional Information (Details)
2415402 - Disclosure - Segment Information - Additional Information (Details)
- R61.htmSegment Information - Disaggregation of Revenue (Details)
2415403 - Disclosure - Segment Information - Disaggregation of Revenue (Details)